Stock Ratings / Health Care / ACHV / options

MYGN (39) QDEL (30) NNNN (45) TKNO (44) ⌘ Pro Terminal →

Achieve Life Sciences Inc. (ACHV) Options Positioning, Max Pain & Unusual Sweeps

$7.19 +4.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.24

Achieve Life Sciences Inc. (ACHV) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $739.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $7.24 (+0.70%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACHV)Realized 20D OHLCV Swing Band: ±12%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY ACHV SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (30% of score)

20D Institutional Volume Accumulation (±12% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (27% of score)

FRED Regime × Technicals: 76% of 52W Range • RSI-14 at 46.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$7.41-13.9% Next Q

Q2 (-2Q)

Grade D$6.38+1.7% Next Q

Q3 (-1Q)

Grade D$6.49+10.8% Next Q

Current

Grade D$7.19-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACHV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACHV currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.45) and Max Pain ($7.55) forces dealer call-delta covering toward $9.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACHV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ACHV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ACHV)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ACHV.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACHV)

✓Walkthrough of ACHV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ACHV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +63.78%▲ ASCENDING CHANNEL

2026-10-30O $7.12H $7.29L $6.57C $7.19VOL 1.38M

RES: $10.45SUP: $6.29SMA50: $7.45SMA200: $5.64

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACHV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACHV Butterfly Map → + Track ACHV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ACHV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACHV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ACHV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACHV)

Health Care Rank #504 of 1016 ⚔️ MYGN vs ACHV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACHV vs. MYGN, QDEL, NNNN, TKNO)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Achieve Life Sciences Inc. (ACHV) ranks #504 by composite RQD confidence (44/100, grade D) and #394 by equity capitalization ($739.9M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. NNNN currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with ACHV at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ACHV ACTIVE Achieve Life Sciences Inc.	D	44/100	—	—	-35.0%	+4.96%	$739.9M	Benchmark Subject
MYGN Myriad Genetics Inc.	D-	39/100	—	69.9%	-35.0%	+0.60%	$638.0M	/mygn-vs-achv →
QDEL QuidelOrtho Corporation	E	30/100	—	—	-35.0%	-1.78%	$943.6M	/qdel-vs-achv →
NNNN Anbio Biotechnology (Class A)	D	45/100	83.6x	87.2%	17.0%	-3.12%	$535.3M	/nnnn-vs-achv →
TKNO Alpha Teknova Inc.	D	44/100	—	33.2%	-21.3%	+2.93%	$499.2M	/tkno-vs-achv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000949858

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Achieve Life Sciences Inc. (ACHV) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$54.6M, operating cash flow of -$49.5M, and free cash flow of -$49.5M (-66.2% YoY). On the balance sheet, ACHV closed FY2025 with $41.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$54.6M	-$49.5M	-$49.5M	$41.8M	—
FY2024 (FY)	2024-12-31	$0	-$39.8M	-$29.8M	-$29.8M	$38.6M	—
FY2023 (FY)	2023-12-31	$0	-$29.8M	-$24.5M	-$24.5M	—	—

3. ACHV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACHV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Achieve Life Sciences Inc. (NASDAQ: ACHV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $7.19 (+4.96% 1D, market cap $739.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ACHV ranks #504 in composite RQD confidence.

How does ACHV compare to MYGN and QDEL in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ACHV carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MYGN (Myriad Genetics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $638.0M) and QDEL (QuidelOrtho Corporation) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $943.6M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ACHV?

Per ACHV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000949858), Achieve Life Sciences Inc. generated $0 in revenue, -$54.6M in net income, and -$49.5M in free cash flow against $41.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ACHV trading relative to its 50-day, 200-day, and 52-week technical levels?

ACHV last traded at $7.19 (+4.96% on volume of 1,375,122 shares), positioning the stock -3.49% below its 50-day simple moving average ($7.45) and +27.48% above its 200-day simple moving average ($5.64). Across its 52-week range of $2.62 to $8.64, ACHV sits at the 75.9% percentile with a 14-day RSI of 46.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($6.33 to $8.05).

ACHV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ACHV's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ACHV.

Direct Sub-Reports: ACHV RQD Cockpit ACHV 12M Forecast ACHV Earnings & Move ACHV Dividends & DRIP ACHV Insiders & 13F ACHV Whale Options ACHV Profit Sankey ACHV News & Why